Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy

Key Points ORR was 67% with venetoclax for 36 patients with CLL refractory to or who relapsed after idelalisib; median PFS has not yet been reached. Common adverse events included mild gastrointestinal events and grade 3/4 cytopenias; no patients experienced tumor lysis syndrome.